Eugenia Cordero-García1,2, Allan Ramos-Esquivel3,4, Warner Alpízar-Alpízar5,6. 1. Department of Pharmacology, Toxicology and Drug Dependence, Faculty of Pharmacy, University of Costa Rica, San José, Costa Rica. 2. Institute of Pharmaceutical Research, University of Costa Rica, San José, Costa Rica. 3. Department of Medical Oncology, Hospital San Juan de Dios, Caja Costarricense de Seguro Social, San José, Costa Rica. 4. Department of Pharmacology, School of Medicine, University of Costa Rica, San José, Costa Rica. 5. Center for Research in Microscopic Structures (CIEMIC for its acronym in Spanish), University of Costa Rica, San José, Costa Rica. 6. Department of Biochemistry, School of Medicine, University of Costa Rica, San José, Costa Rica.
Abstract
BACKGROUND: Gastric cancer is one of the major causes of cancer-related deaths in several Latin-American countries, including Costa Rica. However, determinants of poor outcomes are fairly unknown for patients from this region. The aim of this study was to determine prognostic variables of overall survival (OS) in a cohort of Hispanic patients after curative-intent surgery for gastric cancer. METHODS: We retrospectively evaluated the clinical records of 236 consecutive patients who underwent surgery for advanced gastric cancer at four major hospitals in Costa Rica. Univariate and multivariate Cox proportional models were used to assess the influence of age, sex, clinical stage, adjuvant therapy, type of dissection (D1 vs. D2), extent of gastrectomy (partial vs. total), margin status (R0 vs. R1/2), tumour differentiation, and tumour location on OS. RESULTS: After a median follow-up of 46.5 months, median OS was 47.6 months [95% confidence interval (CI): 34.7-60.4]. There was no survival benefit of adjuvant chemotherapy [hazard ratio (HR): 1.18; 95% CI: 0.70-2.00; P=0.53] or postoperative chemoradiotherapy (CRT) (HR: 1.04; 95% CI: 0.71-1.52; P=0.85) compared to surgery alone. After adjustment for potential confounders, the R0 status was associated with better OS (HR: 0.51; 95% CI: 0.28-0.92; P=0.03). Similarly, clinical stage (III vs. I) (HR: 2.26; 95% CI: 1.39-4.29; P=0.001), poor differentiated (HR: 1.72; 95% CI: 1.22-2.76; P=0.03) and undifferentiated tumours (HR: 2.37; 95% CI: 1.39-4.23; P=0.001) were associated with worse outcomes. CONCLUSIONS: The surgical margin status, clinical stage, and tumour differentiation were predictor variables for OS in this cohort of gastric cancer patients.
BACKGROUND: Gastric cancer is one of the major causes of cancer-related deaths in several Latin-American countries, including Costa Rica. However, determinants of poor outcomes are fairly unknown for patients from this region. The aim of this study was to determine prognostic variables of overall survival (OS) in a cohort of Hispanic patients after curative-intent surgery for gastric cancer. METHODS: We retrospectively evaluated the clinical records of 236 consecutive patients who underwent surgery for advanced gastric cancer at four major hospitals in Costa Rica. Univariate and multivariate Cox proportional models were used to assess the influence of age, sex, clinical stage, adjuvant therapy, type of dissection (D1 vs. D2), extent of gastrectomy (partial vs. total), margin status (R0 vs. R1/2), tumour differentiation, and tumour location on OS. RESULTS: After a median follow-up of 46.5 months, median OS was 47.6 months [95% confidence interval (CI): 34.7-60.4]. There was no survival benefit of adjuvant chemotherapy [hazard ratio (HR): 1.18; 95% CI: 0.70-2.00; P=0.53] or postoperative chemoradiotherapy (CRT) (HR: 1.04; 95% CI: 0.71-1.52; P=0.85) compared to surgery alone. After adjustment for potential confounders, the R0 status was associated with better OS (HR: 0.51; 95% CI: 0.28-0.92; P=0.03). Similarly, clinical stage (III vs. I) (HR: 2.26; 95% CI: 1.39-4.29; P=0.001), poor differentiated (HR: 1.72; 95% CI: 1.22-2.76; P=0.03) and undifferentiated tumours (HR: 2.37; 95% CI: 1.39-4.23; P=0.001) were associated with worse outcomes. CONCLUSIONS: The surgical margin status, clinical stage, and tumour differentiation were predictor variables for OS in this cohort of gastric cancer patients.
Entities:
Keywords:
Gastrectomy; Latin America; prognosis; stomach neoplasm; survival
Authors: Gaya Spolverato; Aslam Ejaz; Yuhree Kim; Malcolm H Squires; George A Poultsides; Ryan C Fields; Carl Schmidt; Sharon M Weber; Konstantinos Votanopoulos; Shishir K Maithel; Timothy M Pawlik Journal: J Am Coll Surg Date: 2014-06-26 Impact factor: 6.113
Authors: Johan L Dikken; Edwin P M Jansen; Annemieke Cats; Berdine Bakker; Henk H Hartgrink; Elma Meershoek-Klein Kranenbarg; Henk Boot; Hein Putter; Koen C M J Peeters; Cornelis J H van de Velde; Marcel Verheij Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: J S Chang; K H Kim; H I Yoon; W J Hyung; S Y Rha; H S Kim; Y C Lee; J S Lim; S H Noh; W S Koom Journal: Br J Surg Date: 2017-02-28 Impact factor: 6.939
Authors: Se Hoon Park; Tae Sung Sohn; Jeeyun Lee; Do Hoon Lim; Min Eui Hong; Kyoung-Mee Kim; Insuk Sohn; Sin Ho Jung; Min Gew Choi; Jun Ho Lee; Jae Moon Bae; Sung Kim; Seung Tae Kim; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: J Kim; C-L Sun; B Mailey; C Prendergast; A Artinyan; S Bhatia; A Pigazzi; J D I Ellenhorn Journal: Ann Oncol Date: 2009-07-21 Impact factor: 32.976
Authors: F De Vita; F Giuliani; M Orditura; E Maiello; G Galizia; N Di Martino; F Montemurro; G Cartenì; L Manzione; S Romito; V Gebbia; F Ciardiello; G Catalano; G Colucci Journal: Ann Oncol Date: 2007-05-24 Impact factor: 32.976
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396